{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:42:48Z","timestamp":1772160168262,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the lipid\u2010lowering efficacy, safety, and adherence of switching from moderate\u2010 or low\u2010intensity statin monotherapy to ezetimibe 10\u2009mg\/rosuvastatin 2.5\u2009mg in Korean patients with type 2 diabetes mellitus (T2DM) and dyslipidaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This multicentre, open\u2010label, single\u2010arm, prospective study enrolled adults with T2DM and LDL\u2010C \u226570\u2009mg\/dL despite \u226512\u2009weeks of moderate or low\u2010intensity statin therapy. Participants received ezetimibe 10\u2009mg\/rosuvastatin 2.5\u2009mg once daily for 12\u2009weeks. The primary endpoint was the proportion achieving LDL\u2010C &lt;70\u2009mg\/dL at Week 12. Secondary endpoints included changes in lipid and glycaemic parameters, subgroup analyses, and safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 639 screened patients, 586 were included in the full analysis set (FAS). At Week 12, 62.3% (95% CI 58.4\u201366.2) achieved LDL\u2010C &lt;70\u2009mg\/dL. Mean LDL\u2010C decreased by 26.0% from 90.9\u2009\u00b1\u200917.2 to 67.3\u2009\u00b1\u200919.3\u2009mg\/dL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Total cholesterol, non\u2013HDL\u2010C, and apoB decreased significantly (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001); HDL\u2010C and triglycerides were unchanged (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.914 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.393, respectively). HbA1c increased by 0.15\u2009\u00b1\u20090.53% and fasting glucose by 3.6\u2009\u00b1\u200924.7\u2009mg\/dL (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). HOMA\u2010IR decreased by \u22120.22\u2009\u00b1\u20093.09, not significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.085). Subgroup analyses showed greater LDL\u2010C reductions in patients with BMI &lt;23\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , prior low\u2010intensity statin use, or pravastatin therapy, and smaller reductions in those receiving GLP\u20101 receptor agonists or thiazolidinediones. Adherence averaged 97.5% (97.4%, \u226580%). Among 591 participants, 9.8% had at least one adverse event, mostly mild and not clinically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to ezetimibe 10 mg\/rosuvastatin 2.5\u2009mg achieved substantial LDL\u2010C reductions, high goal attainment, excellent adherence, and good tolerability in Korean T2DM patients with dyslipidaemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70258","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:37:44Z","timestamp":1762335464000},"page":"906-913","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of switching to ezetimibe 10\u2009mg\/rosuvastatin 2.5\u2009mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (\n                    <scp>EROICA<\/scp>\n                    study)"],"prefix":"10.1111","volume":"28","author":[{"given":"Sangmo","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hanyang University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gangneung Asan Hospital University of Ulsan College of Medicine  Gangneung Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-8412","authenticated-orcid":false,"given":"Sungrae","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St Mary's Hospital, College of Medicine The Catholic University of Korea  Bucheon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung H.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hanyang University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-4675","authenticated-orcid":false,"given":"Eun S.","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Yonsei University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5460-2846","authenticated-orcid":false,"given":"Min K.","family":"Moon","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, SMG\u2013SNU Boramae Medical Center Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Chung\u2010Ang University College of Medicine  Seoul Republic of Korea"},{"name":"Department of Pharmacology Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u2010Oh","family":"Mok","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital Soonchunhyang University School of Medicine  Bucheon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Gachon University Gil Hospital  Incheon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-9965","authenticated-orcid":false,"given":"Cheol\u2010Young","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Kangbuk Hospital Sungkyunkwan University School of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-834X","authenticated-orcid":false,"given":"Chang B.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hanyang University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.2173"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.03.002"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0254"},{"issue":"25","key":"e_1_2_9_6_1","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy SM","year":"2019","journal-title":"Circulation"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2020-0490"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0448"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2017.03.001"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-12-137"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2023.0285"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"issue":"3","key":"e_1_2_9_15_1","first-page":"199","article-title":"Guideline for good clinical practice","volume":"47","author":"ICH Harmonised Tripartite Guideline","year":"2001","journal-title":"J Postgrad Med"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.07.016"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.12.018"},{"issue":"9","key":"e_1_2_9_20_1","first-page":"1317","article-title":"CYP2C9 genetic polymorphism is a potential predictive marker for the efficacy of rosuvastatin therapy","volume":"61","author":"Lin J","year":"2015","journal-title":"Clin Lab"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy182"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70258","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:48:06Z","timestamp":1769719686000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/dom.70258"],"URL":"https:\/\/doi.org\/10.1111\/dom.70258","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70258\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70258\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70258\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70258\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70258\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"2025-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}